These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 35095837)
1. COVID-19 Disease and Dermatomyositis: A Mini-Review. Qian J; Xu H Front Immunol; 2021; 12():747116. PubMed ID: 35095837 [TBL] [Abstract][Full Text] [Related]
2. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. Kang EH; Nakashima R; Mimori T; Kim J; Lee YJ; Lee EB; Song YW BMC Musculoskelet Disord; 2010 Sep; 11():223. PubMed ID: 20875136 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of cutaneous manifestations and myositis-specific antibodies in COVID-19 patients and Anti-PL7 antibodies association with pulmonary radiological severity: A retrospective study. Oddenino GA; Canepa P; Cozzani E; Gasparini G; Garlaschi A; Roccatagliata L; Schiavetti I; Parodi A Int J Immunopathol Pharmacol; 2024; 38():3946320241260295. PubMed ID: 39052920 [TBL] [Abstract][Full Text] [Related]
4. What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19? De Lorenzis E; Natalello G; Gigante L; Verardi L; Bosello SL; Gremese E Autoimmun Rev; 2020 Nov; 19(11):102666. PubMed ID: 32942036 [No Abstract] [Full Text] [Related]
5. Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review. Gonzalez D; Gupta L; Murthy V; Gonzalez EB; Williamson KA; Makol A; Tan CL; Sulaiman FN; Shahril NS; Isa LM; Martín-Nares E; Aggarwal R Rheumatol Int; 2022 Sep; 42(9):1629-1641. PubMed ID: 35661906 [TBL] [Abstract][Full Text] [Related]
6. COVID-19 and Myositis: What We Know So Far. Saud A; Naveen R; Aggarwal R; Gupta L Curr Rheumatol Rep; 2021 Jul; 23(8):63. PubMed ID: 34216297 [TBL] [Abstract][Full Text] [Related]
7. New-onset dermatomyositis following COVID-19: A case report. Shimizu H; Matsumoto H; Sasajima T; Suzuki T; Okubo Y; Fujita Y; Temmoku J; Yoshida S; Asano T; Ohira H; Ejiri Y; Migita K Front Immunol; 2022; 13():1002329. PubMed ID: 36353621 [TBL] [Abstract][Full Text] [Related]
8. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease. Li X; Liu Y; Cheng L; Huang Y; Yan S; Li H; Zhan H; Li Y J Clin Lab Anal; 2022 Nov; 36(11):e24726. PubMed ID: 36221983 [TBL] [Abstract][Full Text] [Related]
9. Elevated serum B-cell activating factor levels in patients with dermatomyositis: Association with interstitial lung disease. Matsushita T; Kobayashi T; Kano M; Hamaguchi Y; Takehara K J Dermatol; 2019 Dec; 46(12):1190-1196. PubMed ID: 31631384 [TBL] [Abstract][Full Text] [Related]
11. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268 [TBL] [Abstract][Full Text] [Related]
12. Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age. Yamaguchi K; Yamaguchi A; Onuki Y; Itai M; Kashiwagi C; Takehara K; Aoki S; Kanaya A; Taguchi K; Umetsu K; Oshima K; Uchida M; Kimura H; Kasahara M; Takemura M; Hara K; Sekiguchi A; Motegi SI; Muro Y; Nakasatomi M; Motohashi R; Sakairi T; Nakagawa J; Hiromura K; Obokata M; Kurabayashi M; Maeno T Mod Rheumatol; 2021 Jan; 31(1):177-185. PubMed ID: 32149542 [TBL] [Abstract][Full Text] [Related]
13. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis. Wu W; Guo L; Fu Y; Wang K; Zhang D; Xu W; Chen Z; Ye S Clin Rev Allergy Immunol; 2021 Apr; 60(2):293-304. PubMed ID: 33405101 [TBL] [Abstract][Full Text] [Related]
14. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report. Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894 [TBL] [Abstract][Full Text] [Related]
15. Dermatomyositis sine myositis and antisynthetase syndrome. Climent-Albaladejo A; Saiz-Cuenca E; Rosique-Roman J; Caballero-Rodriguez J; Galvez-Munoz J Joint Bone Spine; 2002 Jan; 69(1):72-5. PubMed ID: 11858361 [TBL] [Abstract][Full Text] [Related]
16. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. Gerami P; Schope JM; McDonald L; Walling HW; Sontheimer RD J Am Acad Dermatol; 2006 Apr; 54(4):597-613. PubMed ID: 16546580 [TBL] [Abstract][Full Text] [Related]
18. Inflammatory Myopathies with Cutaneous Involvement: from Diagnosis to Therapy. Dourmishev LA Folia Med (Plovdiv); 2017 Mar; 59(1):7-13. PubMed ID: 28384112 [TBL] [Abstract][Full Text] [Related]
19. COVID-19 as a putative trigger of anti-MDA5-associated dermatomyositis with acute respiratory distress syndrome (ARDS) requiring lung transplantation, a case report. Anderle K; Machold K; Kiener HP; Bormann D; Hoetzenecker K; Geleff S; Prosch H; Laccone F; Heil PM; Petzelbauer P; Aletaha D; Blüml S; Kastrati K BMC Rheumatol; 2022 Jul; 6(1):42. PubMed ID: 35821079 [TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report. Syrmou V; Liaskos C; Ntavari N; Mitsimponas K; Simopoulou T; Alexiou I; Vlychou M; Katsiari CG; Bogdanos DP Immunol Res; 2023 Aug; 71(4):537-546. PubMed ID: 36928720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]